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Abstract
Background: It has been recognized that phospholipase A2 (PLA2) is a crucial component of snake
venom, which contributes greatly to snake venom induced inflammation in man. However, the
mechanisms through which N49 PLA2 provoke inflammation remain unclear. Recently, a N49 PLA2,
TM-N49 from Protobothrops mucrosquamatus crude venom was characterized in our laboratory.
Since the purification procedure developed is able to supply us with relatively large quantity of
highly purified TM-N49, we investigated the ability of TM-N49 in induction of inflammation.
Results: The results showed that TM-N49 provoked a dose dependent increase in microvascular
leakage in the skin of rats. The potency of TM-N49 in induction of skin edema appeared similar
potency of bradykinin and histamine. Pretreatment of rats with compound 48/80 diminished TM-
N49 induced skin reaction and reduced mast cell numbers in rats. Ginkgolide B and
cyproheptadine, but not terfenadine and quinacrine, inhibited TM-N49 elicited microvascular
leakage when they were co-injected with the stimulus to rat skin. Moreover, TM-N49 was found
to induce histamine release from human colon, lung and tonsil mast cells, and both metabolic
inhibitors and pertussis toxin were capable of inhibiting TM-N49 elicited histamine release. TM-
N49 induced mast cell accumulation in the peritoneum of mice, which was inhibited by co-injection
of ginkgolide B, cyproheptadine and terfenadine. Intravenous injection of monoclonal antibodies
against CD18, ICAM-1 and CD11a also blocked TM-N49 induced mast cell accumulation.
Conclusion: TM-N49 is a potent stimulus for skin edema, mast cell activation and accumulation.
Background
Snake venoms are chemically complex mixtures of phar-
macologically active proteins or peptides, which serve not
only as a source of digestive enzymes, but also play an
important role in immobilizing the prey and acting as
offensive weapons. They can target multiple tissues, caus-
ing simultaneous damage of multiple physiological sys-
tems. One of the components which contribute
significantly to the lethality of snake venoms is phosphol-
ipase A2 (PLA2) (EC 3.1.1.4) [1]. PLA2 constitutes a family
of structurally related proteins hydrolyze phospholipids
at the sn-2 position in a calcium-dependent manner,
releasing fatty acids and lysophospholipids [2]. Snake
venom PLA2s are low-molecular weight (13,000–14,000
Da), secretory phospholipases containing seven disulfide
bonds. Based on their amino acid sequence and disulfide
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bond pattern, snake venom PLA2s are classified into group
I PLA2 (from Elapidae/Hydrophidae) or group II PLA2
(from Crotalidae/Viperidae) [3]. Usually, the group II
PLA2s are further subdivided into two major subgroups:
the Asp-49 PLA2s (D49 PLA2s), which have an aspartic
acid at position 49 and high catalytic activity towards arti-
ficial phospholipid substrates; and Lys-49 PLA2s (K49
PLA2s), which have a lysine substitutes at position 49 and
very low or no hydrolytic activity towards artificial phos-
pholipid substrates [4,5]. Recently, a unique subgroup of
snake venom group II PLA2, named N49 PLA2 subgroup
was identified from several Asiatic snake venoms [6-8].
The N49 PLA2 was found to differ from the other sub-
groups in its structure and biological activities.
Besides the digestive function, snake PLA2s exhibit sever-
alother pharmacological properties including antiplatelet
[9,10], anticoagulant [11], hemolytic [9], neurotoxic (pre-
synaptic) [12], myotoxic [13-15]. They have also been
employed widely as pharmacological tools to investigate
the roles of these enzymes in diverse models of experi-
mental inflammatory processes such as edema, inflamma-
tory cell infiltration and mast cells activation [15-20].
Mast cells are primarily located in mucosal and perivascu-
lar areas of various tissues, which play an important role
in body defense processes. Recent studies found that mast
cells can be activated by snake venom and release carbox-
ypeptidase A and possibly other proteases, which can
degrade venom components [21,22]. Our former study
also showed that atrahagin, a metalloprotienase purified
from  Naja atra snake, could potently activate human
colon, lung and tonsil mast cells to release histamine [23].
Several snake venom PLA2s were reported to be able to
activate the rat mast cells, to induce microvascular leakage
and inflammatory cell accumulation at the sites of inflam-
mation [15-20]. However, little is known of the action of
N49 PLA2s on human mast cells, and the mechanisms
through which N49 PLA2 induces microvascular leakage
and inflammatory cell accumulation still remain obscure.
Therefore, we investigated the mechanisms of TM-N49 [6]
in induction of microvascular leakage and mast cell accu-
mulation and activation in the present study.
Results
Purification and characterization of TM-N49
Approximately 15 mg of TM-N49 was obtained from 1.5
g Protobothrops mucrosquamatus crude venom following the
procedures described above. The purity of the PLA2 was at
least 98% as assessed by SDS-PAGE, HPLC and mass spec-
trometry analysis.
Induction of microvascular leakage by TM-N49
TM-N49 at doses of 0.15–5.0 μg provoked a dose depend-
ent increase in microvascular leakage in the skin of rats at
20 min following injection. As little as 0.15 μg was able to
stimulate significant skin edema after injection indicating
that TM-N49 is a potent stimulus. The potency of TM-N49
in induction of skin edema is similar to that of bradykinin
and histamine on the weight basis (all at 5 μg) (Figure 1).
Pretreatment of rats with compound 48/80 for a period
longer than 72 h clearly diminished the skin responsive-
ness of the rats to TM-N49 and histamine (Figure 2A), and
dramatically reduced mast cell numbers in the peritoneal
lavage fluid of these rats (Figure 2B).
Influence of anti-inflammatory compounds on 
microvascular leakage
Ginkgolide B at a dose of 5 μg inhibited 73.5%, 77.5%
and 40% microvascular leakage induced by PAF, hista-
mine and TM-N49, respectively when it was co-injected
with these stimuli. Cyproheptadine at a dose of 5 μg also
inhibited 85.6% and 94.7% histamine and TM-N49 elic-
ited microvascular leakage. Terfenadine and quinacrine at
the dose of 5 μg had little effect on TM-N49 provoked
microvascular leakage in rat skin (Figure 3). All anti-
inflammatory compounds tested by themselves had no
significant effect on the microvascular leakage in rat skin
(data not shown).
Induction of histamine release from mast cells by TM-N49
A dose dependent release of histamine from colon, lung
and tonsil mast cells was observed when various concen-
trations of TM-N49 were incubated with cells for 15 min.
As low as 0.03 μg/ml of TM-N49 was able to stimulate sig-
nificant histamine release from human colon and lung
mast cells, but to stimulate a similar level of histamine
release from tonsil mast cells a minimum of 3.0 μg/ml of
TM-N49 was required. While TM-N49 at a concentration
of 30 μg/ml was able to provoke approximately 30%, 15%
and 62% net histamine release, anti-IgE antibody at a con-
centration of 10 μg/ml stimulated approximately 17%,
17% and 11% net histamine release from colon, lung and
tonsil mast cells, respectively in the parallel experiments.
At a concentration of 30 μg/ml, TM-N49 induced also sig-
nificant histamine release from colon and tonsil mast cells
when calcium and magnesium were absent in the chal-
lenge buffer (Figure 4).
Time course for TM-N49 induced histamine release
Immediately after adding 30 μg/ml of TM-N49 to cells,
histamine release from colon, lung and tonsil mast cells
occurred. Approximately 26.8%, 26.1% and 44.1% of the
maximum of histamine release were observed following
incubation of TM-N49 with colon, lung and tonsil cells,
respectively for 1 min. At the same time point, anti-IgE
antibody at 10 μg/ml induced 12.5%, 26.2% and 34.3%
of the maximum of histamine release, and calcium iono-
phore at a concentration of 1 μg/ml provoked 34.7%,
58.1% and 44.1% of the maximum of histamine releaseBMC Immunology 2009, 10:21 http://www.biomedcentral.com/1471-2172/10/21
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from colon, lung and tonsil mast cells, respectively (Figure
5).
The peak of histamine released from colon, tonsil and
lung mast cells in response to TM-N49 occurred at 10, 10
and 8 min following TM-N49 being added to cells,
whereas in the parallel experiments, the peak histamine
release induced by anti-IgE antibody occurred at 7, 10 and
7 min for colon, lung and tonsil mast cells, respectively.
Similarly, the peak histamine release provoked by calcium
ionophore appeared at 6, 7 and 8 min for colon, lung and
tonsil mast cells, respectively. The maximum release of
histamine was then sustained at least to 20 min (Figure 5).
Effects of metabolic inhibitors and pertussis toxin on 
histamine release
When cells were pretreated with metabolic inhibitors for
40 min 3 μg/ml of TM-N49 induced histamine release
Effect of TM-N49 on rat dermal microvascular leakage Figure 1
Effect of TM-N49 on rat dermal microvascular leakage. Various doses of TM-N49 were injected into the skin of rat for 
20 min. Also shown are the responses to BSA, bradykinin and histamine alone at a dose of 5 μg and normal saline control. Skin 
reaction represented the area of Evan's blue extravasation. Data are displayed as a boxplot, which indicates the median, inter-
quartile range, the largest and smallest values other than outliers (O) (defined as those which are more than 1.5 box lengths 
from the median) for 6 animals in each group. * P < 0.05 compared with the response to the diluent only control animals.BMC Immunology 2009, 10:21 http://www.biomedcentral.com/1471-2172/10/21
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Influence of compound 48/80 on rat dermal microvascular leakage induced by TM-N49 and histamine (A), and on mast cell  numbers in the peritoneum of rats (B) Figure 2
Influence of compound 48/80 on rat dermal microvascular leakage induced by TM-N49 and histamine (A), and 
on mast cell numbers in the peritoneum of rats (B). Rats were intra-peritoneally injected with compound 48/80 at a 
dose of 0.6 mg·kg-1 for 6 h, twice a day for 3 days, and doubled dose in day 4 before TM-N49 (5 μg) or histamine (5 μg) being 
administrated for 20 min. Skin reaction represented the area of Evan's blue extravasation. Data are displayed as a boxplot, 
which indicates the median, interquartile range, the largest and smallest values other than outliers (O) (defined as those which 
are more than 1.5 box lengths from the median) for 6 animals in each group. In (A), * P < 0.05 compared with the correspond-
ing response to untreated animals and in (B), * P < 0.05 compared with the response to untreated animals.BMC Immunology 2009, 10:21 http://www.biomedcentral.com/1471-2172/10/21
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from colon, lung and tonsil mast cells was completely
abolished. However, metabolic inhibitors exhibited little
effect on histamine release from tonsil mast cells when 30
μg/ml of TM-N49 was added to cells. Similarly, metabolic
inhibitors dramatically inhibited anti-IgE antibody pro-
voked histamine release from colon, lung and tonsil mast
cells, but had relatively less efficient inhibition of calcium
ionophore elicited histamine release from mast cells
(Table 1). Pretreatment of cells with pertussis toxin for 4
h reduced dramatically their responses to TM-N49 and
anti-IgE antibody, but had no significant effect on their
ability to release histamine in response to calcium iono-
phore (Table 2).
Induction of mast cell accumulation by TM-N49
As early as 10 min following injection, 5 μg of TM-N49
was able to induce significant mast cell accumulation in
the peritoneum of mice. The mast cell accumulation
induced by TM-N49 appeared to at least maintain for 16
h. As little as 0.5 μg of TM-N49 was able to potently
Influence of anti-inflammatory drugs on rat dermal microvascular leakage induced by TM-N49 (5 μg), bradykinin (5 μg), PAF (5  μg) and histamine (5 μg) Figure 3
Influence of anti-inflammatory drugs on rat dermal microvascular leakage induced by TM-N49 (5 μg), bradyki-
nin (5 μg), PAF (5 μg) and histamine (5 μg). Ginkgolide (GG, 5 μg), cyproheptadine (CH, 5 μg), terfenadine (TF, 5 μg) or 
quinacrine (QC, 5 μg) were co-injected with TM-N49, bradykinin or histamine, respectively for 20 min, whereas PAF was only 
co-injected with GG. Skin reaction represented the area of Evan's blue extravasation. Data are displayed as a boxplot, which 
indicates the median, interquartile range, the largest and smallest values other than outliers (O) (defined as those which are 
more than 1.5 box lengths from the median) for 6 animals in each group. * P < 0.05 compared with the response to the corre-
sponding uninhibited control animals.BMC Immunology 2009, 10:21 http://www.biomedcentral.com/1471-2172/10/21
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induce mast cell infiltration in the peritoneum of mice at
6 h and 16 h following injection (Figure 6). However, rel-
ative mast cell number in mouse peritoneum was not sig-
nificantly increased except for 5 μg of TM-N49 injected for
2 h. At 50 μg, TM-N49 markedly reduced relative number
of mast cells at all the time points examined following
injection (Table 3).
Effects of anti-inflammatory compounds and blocking 
antibodies on mast cell accumulation
When co-injected, ginkgolide B, cyproheptadine and ter-
fenadine inhibited 85.6%, 80% and 100% TM-N49
induced mast cell accumulation in the peritoneum of
mice, respectively. However, quinacrine did not signifi-
cantly alter the extent of TM-N49 induced mast cell accu-
mulation. At the dose tested, ginkgolide B,
cyproheptadine, terfenadine and quinacrine by them-
selves failed to induce mast cell accumulation in the peri-
toneum of mice (Table 4).
Intravenous injection of monoclonal antibodies against
CD18, ICAM-1 and CD11a 30 min prior to intra-perito-
neal injection of the PLA2 blocked TM-N49 induced mast
cell accumulation by 70% and 99%, respectively. Mono-
clonal antibodies against L-selectin failed to diminish TM-
N49 induced mast cell accumulation in the peritoneum of
Effects of TM-N49 on histamine release from colon, lung and tonsil mast cells in the presence or absence of exogenous calcium  and magnesium Figure 4
Effects of TM-N49 on histamine release from colon, lung and tonsil mast cells in the presence or absence of 
exogenous calcium and magnesium. The values shown are mean ± SE for four to five separate experiments. Various con-
centrations of TM-N49 were incubated with cells for 15 min before termination of the reactions. * P < 0.05 compared with the 
response to the corresponding buffer alone group, †P < 0.05 compared with the response to the corresponding group in the 
absence of calcium and magnesium.BMC Immunology 2009, 10:21 http://www.biomedcentral.com/1471-2172/10/21
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Time course for histamine release from colon, lung and tonsil mast cells induced by TM-N49 (30 μg/ml), anti-IgE antibody (10  μg/ml) and calcium ionophore (1 μg/ml) Figure 5
Time course for histamine release from colon, lung and tonsil mast cells induced by TM-N49 (30 μg/ml), anti-
IgE antibody (10 μg/ml) and calcium ionophore (1 μg/ml). The values shown are mean ± SE of the percentage of maxi-
mum histamine release, which equals (actual net histamine release/maximum net histamine release induced by the testing com-
pound) × 100%, for four to five separate experiments.BMC Immunology 2009, 10:21 http://www.biomedcentral.com/1471-2172/10/21
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mice. Normal rat and hamster IgG isotype controls tested
had little effect on TM-N49 induced mast cell accumula-
tion (Table 5).
Discussion
As a novel subgroup of snake venom group II PLA2, the
proinflammatory activities of N49 PLA2 have not yet been
studied. Therefore, this is the first study to investigate the
potential actions of N49 PLA2 in inflammation. TM-N49
was found to be a potent stimulus of microvascular leak-
age in the skin of rats. The potency of this unique, inactive
PLA2 in induction of microvascular leakage is similar to
the potency of bradykinin and histamine on a molar
basis. Therefore it is not difficult to anticipate that TM-
N49 by itself should be able to induce severe inflamma-
tory reactions upon snake bite.
Since histamine/5-HT antagonist cyproheptadine abol-
ished the TM-N49-induced microvascular leakage, but
selective histamine H1 receptor antagonist terfenadine did
not, the action of TM-N49 on skin edema seems to be his-
tamine independent. It is likely that 5-HT and other mast
cell products, such as PAF, serine proteases, leukotrienes,
prostaglandins are involved in the process [24]. Indeed, it
was observed that ginkgolide B, a PAF receptor antagonist
inhibited microvascular leakage induced by TM-N49, sug-
gesting that PAF was involved in the microvascular leak-
age process. Mast cell mediated edema formation in
response to different snake venom PLA2 has been reported
previously. Thus, PLA2 from Vipera russeli, Naja mocam-
bique and honey bee produced a rapid but transient oede-
matous response in rat paw [25]. Bothropstoxin-I and
bothropstoxin-II, two K49 PLA2s isolated from Bothrops
jararacussu snake venom caused dose-dependent rat paw
and skin oedema formation [17]. PLA2s from Crotalus
durissus cascavella, Crotalus durissus collilineatus and Cro-
talus durissus terrificus venoms increased the vascular per-
meability in the rat skin [26]. However, the observed
reduction of mast cell numbers by injection of compound
48/80 hardly affects the inflammatory potential of TM-
N49: even a 10-fold reduction in detectable mast cells
does not result in a significant reduction of extravasation.
This implied that mast cell activation may not be the rele-
vant mechanism for TM-N49 induced skin edema. It is
difficult to exclude the possibility that TM-N49 bound to
a receptor of PLA2  and caused microvascular leakage,
though the latter has not yet been identified. Recently, it
was found that snake venom catalytically inactive PLA2
homologue could binds to vascular endothelial growth
factor receptor-2 via a C-terminal loop region, exhibiting
mast cell unrelated mechanism for the increased the vas-
cular permeability [27].
In order to study the activation of mast cells by TM-N49,
mast cell challenge experiments were performed. TM-N49
can activate human colon, lung and tonsil mast cells in a
Table 1: The effect of metabolic inhibitors on TM-N49 induced histamine release from human mast cells
Compound
(μg/ml)
Net histamine release (%)
Without metabolic inhibitors With metabolic inhibitors
Lung Colon Tonsil Lung Colon Tonsil
TM-N49 3.0 9.3 ± 1.9 13.5 ± 3.0 8.0 ± 2.0 0.4 ± 0.4* 0.4 ± 0.7* 0.8 ± 0.6*
30 14.7 ± 4.7 29.6 ± 6.8 62.0 ± 8.5 1.6 ± 0.9* 0.4 ± 1.4* 49.3 ± 7.5
Anti-IgE 10 17.3 ± 5.4 17.4 ± 5.1 11.1 ± 3.4 0.7 ± 1.7* 0.1 ± 0.8* 2.2 ± 1.5*
CI 0.5 24.4 ± 6.3 38.8 ± 4.6 37 ± 9.3 5.3 ± 5.5* 2.1 ± 0.7* 6.4 ± 2.9*
The values shown are mean ± SE for four to five separate experiments performed in duplicate. Cells were incubated with metabolic inhibitors 2-
deoxy-D-glucose (10 mM) and antimycin A (1 μM) for 40 min at 37°C before challenging with stimulus. * P < 0.05 compared with the corresponding 
uninhibited controls.
Table 2: The effect of pertussis toxin on TM-N49 induced histamine release from human mast cells
Compound
(μg/ml)
Net histamine release (%)
Without pertussis toxin With pertussis toxin
Lung Colon Tonsil Lung Colon Tonsil
TM-N49 3.0 9.3 ± 1.9 13.5 ± 3.0 8.0 ± 2.0 0.8 ± 1.8* 0.1 ± 2.2* 1.5 ± 1.3*
30 14.7 ± 4.7 29.6 ± 6.8 62.0 ± 8.5 4.0 ± 0.6* 3.9 ± 3.9* 31.9 ± 9.2*
Anti-IgE 10 17.3 ± 5.4 17.4 ± 5.1 11.1 ± 3.4 2.1 ± 1.1* 0.9 ± 1.2* 3.0 ± 0.3*
CI 0.5 24.4 ± 6.3 38.8 ± 4.6 37 ± 9.3 19.6 ± 4.8 30.4 ± 2.8 20.4 ± 4.4
The values shown are mean ± SE for four to five separate experiments performed in duplicate. Cells were incubated with1.0 μg/ml pertussis toxin 
for 4 h at 37°C before challenging with stimulus. * P < 0.05 compared with the corresponding uninhibited controls.BMC Immunology 2009, 10:21 http://www.biomedcentral.com/1471-2172/10/21
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dose dependent manner. It was discovered further that
TM-N49 induced mast cell degranulation is an energy
consuming process and involved a G protein coupled
receptor in mast cells [28] as both metabolic inhibitors
and pertussis toxin were capable of inhibiting TM-N49
elicited histamine release from mast cells. It was reported
previously that PLA2s were able to directly activate rat
mast cells in vitro [17,20,29]. The action of D49 PLA2s on
rat mast cells was dependent on their catalytic activity
[16,30], whereas the influence of K49 PLA2s, which pos-
sess negligible catalytic activity, on rat mast cells was
through a heparin-sensitive mechanism [17]. Removal of
Ca2+ and Mg2+ from challenge buffer greatly reduced the
cell response to the stimulation of TM-N49 indicated that
exogenous calcium and magnesium ions were crucial for
mast cell degranulation induced by TM-N49. The
increased serotonin level in mouse peritoneal lavage fluid
supplied further evidence on TM-N49 causing mast cell
degranulation in rats as mast cells are major source (if not
the only source) of serotonin in mouse peritoneum. The
most relevant mast cell population in regard to snake bites
would be skin mast cells which differ in phenotype and
activating stimuli from other mast cell populations. From
those populations investigated, tonsil mast cells most
closely resemble skin mast cells [31]. Interestingly, as
shown in figure 4, tonsil mast cells only responded to
Effect of TM-N49 (TM) on mast cell numbers in mouse peritoneum Figure 6
Effect of TM-N49 (TM) on mast cell numbers in mouse peritoneum. Various doses of TM-N49 were injected into the 
peritoneum of mice for 10 min, 2 h, 6 h or 16 h. Also shown are the responses to BSA and normal saline control. Data are dis-
played as a boxplot, which indicates the median, interquartile range, the largest and smallest values other than outliers (O) 
(defined as those which are more than 1.5 box lengths from the median) for 6 animals in each group. * P < 0.05 compared with 
the response to the corresponding diluent only control animals.
Table 3: Effect of TM-N49 on relative mast cell numbers in mouse peritoneum following injection.
TM-N49 (μg) Percentage of mast cells in total nucleated cells
10 min 2 h 6 h 16 h
Saline 0.49(0.40–0.96) 0.45(0.31–1.30) 0.56(0.23–0.76) 0.85(0.29–1.88)
50 0.16(0.06–0.35)* 0.24(0.08–0.78)* 0.36(0.21–0.90) 0.05(0.03–0.11)*
5.0 0.76 (0.44–1.11) 1.05(0.60–1.77)* 0.67(0.29–1.76) 0.51 (0.22–1.36)
0.5 n.d n.d 0.61(0.39–1.00) 0.63 (0.27–1.10)
0.05 n.d n.d 0.90(0.39–2.67) 1.10 (0.47–1.31)
Various doses of TM-N49 were injected into the peritoneum of mice for 10 min, 2 h, 6 h or 16 h. Also shown are the responses to normal saline 
control. Relative number of mast cells was defined as the percentage of mast cell in total nucleated cells. * P < 0.05 compared with the response to 
saline alone.BMC Immunology 2009, 10:21 http://www.biomedcentral.com/1471-2172/10/21
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rather high concentrations of TM-N49, and the overall
release (~7%) is very little compared to other venom com-
ponents (e.g. atrahagin, induces 26% histamine release)
[23]. TM-N49 at 30 μg appears to be toxic, as the observed
release is later shown to be Ca2+-independent. This, again,
indicates that mast cell activation may not be the relevant
mechanism for TM-N49 induced inflammation.
With a mouse peritoneal model, it was found for the first
time that snake venom PLA2 could induce mast cell accu-
mulation even at 10 min following injection. This
appeared not a mast cell-specific effect since the relative
number of mast cells in total nucleated cells was not sig-
nificantly altered. The action of TM-N49 in induction of
mast cell accumulation could be inhibited by co-injection
of TM-N49 with ginkgolide B, cyproheptadine and ter-
fenadine, suggesting that histamine, 5-HT and PAF may
play a role in mast cell accumulation induced by TM-N49.
Antibodies specific for CD18, CD11a and ICAM-1
blocked TM-N49 induced mast cell accumulation, while
L-selectin specific antibody failed to do so. These observa-
tions suggested that LFA-1 (CD11a/CD18) and ICAM-1,
but not L-selectin were involved in the TM-N49 induced
mast cell migration process. Involvement of CD11a/
CD18 and ICAM-1 in mast cell migration was reported
previously with Saban et al. [32,33]. Since mast cells and
endothelial cells express both LFA-1 and ICAM-1 [32,33],
we believe that CD11/CD18 and ICAM-1 are important
adhesion molecules for TM-N49 induced mast cell migra-
tion. The increase in mast cell numbers could be regarded
as a beneficial host response since mast cells were shown
to be able to detoxify venom components [21].
Conclusion
A novel snake venom group II PLA2, TM-N49 was able to
induce a dramatic increase in microvascular permeability
in the skin of rats. The action of TM-N49 appeared to be
unrelated to the activation of mast cells. Indeed, it was
confirmed that TM-N49 was able to stimulate mast cell
degranulation and accumulation. The ability of TM-N49
in induction of microvascular leakage, mast cell degranu-
lation and mast cell infiltration implicates that it is a
potent proinflammatory factor in snake venom.
Methods
Reagents
Protobothrops mucrosquamatus crude venom was obtained
from the stock of the Kunming Institute of Zoology, the
Chinese Academy of Sciences. SP-sephadex C-25, heparin
sepharose (FF) and superdex 75 were from LKB Pharmacia
(Uppsala, Sweden). The following compounds were pur-
chased from Sigma (St. Louis, USA): egg phosphatidyl
choline, Triton X-100, trifluoroacetic acid, honey bee
venom phospholipase A2, platelet activating factor (PAF),
cyproheptadine, ginkgolide B, heparin, collagenase (type
I), hyaluronidase (type I), soybean trypsin inhibitor
(SBTI), bovine serum albumin (BSA, fraction V), penicil-
lin and streptomycin, calcium ionophore A23187,
antimycin A, 2-deoxy-D-glucose, pertussis toxin. Quina-
Table 4: The influence of anti-inflammatory compounds on TM-N49 (5 μg) induced mast cell accumulation in mouse peritoneum
Compound injected Number of mast cells (× 103)
Saline 14.6 (6.1 – 23)
TM-N49 49.3 (20.3 – 65.9)
Ginkgolide B 5 mg·kg-1 26.2 (9.1 – 41)
Ginkgolide B 5 mg·kg-1 + TM-N49 19.6 (10 – 26)*
Cyproheptadine 2 mg·kg-1 6.2 (1.5 – 17.2)
Cyproheptadine 2 mg·kg-1 + TM-N49 21.9 (10.1 – 28.7)*
Terfenadine 2 mg·kg-1 11.0 (5.8 – 20)
Terfenadine 2 mg·kg-1 + TM-N49 9.5 (4.0 – 13.2)*
Quinacrine 10 mg·kg-1 11.5 (5.9 – 18.1)
Quinacrine 10 mg·kg-1 + TM-N49 59.7 (40.5 – 73.3)
The values shown are medians (range) for six separate experiments. Compounds were injected into the mouse peritoneum for 6 h before 
peritoneal lavage fluid being collected. * P < 0.05 compared with the response to TM-N49 alone.
Table 5: The influence of blocking antibodies (Ab) against cell 
adhesion molecules on TM-N49 (5.0 μg) induced mast cell 
accumulation in mouse peritoneum
Compound injected Number of mast cells (× 103)
Saline 14.6 (6.1 – 23)
TM-N49 49.3 (20.3 – 65.9)
L-selectin Ab + TM-N49 38.0 (19.1 – 68.8)
LFA-1 Ab + TM-N49 33.7 (18.9 – 55.2) *
CD18 Ab + TM-N49 25.1 (10.4 – 39.8)*
ICAM-1 Ab + TM-N49 14.8 (9.6 – 32.0)*
Hamster IgG1 + TM-N49 39.8 (17.0 – 63.1)
Rat IgG2a + TM-N49 43.3 (19.3 – 58.0)
The values shown are medians (range) for six separate experiments. 
Monoclonal antibodies (all at a dose of 1 mg·kg-1) against the adhesion 
molecules L-selectin, LFA-1, CD18 and ICAM-1 were intravenously 
injected, respectively for 30 min before intra-peritoneal injection of 5 
μg of TM-N49 for 6 h. * P < 0.05 compared with the response to TM-
N49 alone.BMC Immunology 2009, 10:21 http://www.biomedcentral.com/1471-2172/10/21
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crine was from Calbiochem (San Diego, CA, USA). Rea-
gents for sodium dodecyl- sulphate-polyacrylamine gel
electrophoresis (SDS-PAGE) were from Bio-Rad Laborato-
ries Inc (Hercules, USA). Coomassie Plus™ assay kit was
from Pierce Chemical Co (Rockford, IL, USA). PolyATract
system 1000 kit and Reverse transcription system kit were
from Promega Biotech (Madison, WI, USA). Goat anti-
human IgE (inactivated) was from Serotec (Kidlington,
Oxford, UK). Fetal calf serum (FCS) and minimum essen-
tial medium (MEM) containing 25 mM N-2-hydroxy-
lethylpiperazine-N'-2 -ethane sulphonic acid (HEPES)
were from Gibco (Paisley, Renfrewshire, UK). Rat mono-
clonal antibodies, anti-mouse CD 11a [lymphocyte func-
tion-associated antigen 1(LFA-1) α chain], clone M17/4;
anti-mouse CD 62L (L-selectin), clone MEL-14; anti-
mouse CD18 (integrin β2 chain), clone M18/2; rat IgG2a
isotype standard, clone R35-95; hamster anti-mouse
CD54 [intercellular adhesion molecule 1 (ICAM-1)] mon-
oclonal antibody, clone 3E2; hamster IgG1 isotype stand-
ard, clone A19-3 were from BD Biosciences Pharmigen
(CA, USA). Hepes and all other chemicals were of analyt-
ical grade. BALB/c mice (20–25 g) and Wistar rat (180–
220 g) were bred and reared under strict ethical condi-
tions according to international recommendation.
Purification of TM-N49
TM-N49 was isolated from Protobothrops mucrosquamatus
crude venom following the procedures described previ-
ously [6]. Briefly, the lyophilized venom (1.5 g) was dis-
solved in 20 ml of 50 mM sodium phosphate buffer (pH
5.8) and loaded on a SP-sephadex C-25 column equili-
brated with the same buffer. The absorbed proteins were
eluted with a linear gradient of NaCl (0–0.8 M) in 50 mM
sodium phosphate (pH 5.8). The fractions in peak 9 were
collected, lyophilized, and then dissolved in a running
buffer containing 25 mM sodium phosphate (pH 5.8) and
0.15 M NaCl. Superdex 75 column was used to further iso-
late TM-N49 and the fractions 50–56 in the main protein
peak was collected and loaded on a heparin-sepharose
(FF) column equilibrated with a 25 mM sodium phos-
phate buffer (pH 5.8). The absorbed proteins were eluted
with a linear gradient of NaCl (0–0.8 M) in 25 mM
sodium phosphate (pH 5.8). The fractions 40–47 in the
main protein peak eluted from heparin agarose were col-
lected, lyophilized, dissolved in 0.1% trifluoroacetic acid
(v/v) and loaded on a reverse-phase C18 high performance
liquid chromatography colomn (Symmetry 300™, 5 μM;
Waters Corporation, Milford, Massachusetts, USA). The
elution was performed with 0.1% trifluoroacetic acid and
a gradient of 15–75% buffer B (containing 100% ace-
tonitrile (v/v) and 0.1% trifluoroacetic acid) over 60 min
at a flow rate of 1 ml/min. The fractions in main protein
peak representing the purified TM-N49 were pooled,
lyophilized and analyzed with mass spectrometer and
stored at -20°C until use. Protein concentration was deter-
mined by a modified Bradford method [34] using a
Coomassie Plus™ assay kit with BSA as standard. The PLA2
activity was routinely assayed by a titration method using
egg yolk as substrate according to Ishimaru et al. [35], and
by a colorimetric assay using L-phosphatidylcholine as
substrate according to de Ajaujo and Radvanyi [36].
Honey bee PLA2 was employed as positive control.
Induction of microvascular leakage
Microvascular leakage experiments were performed
mainly following the procedures described previously by
He et al. [37]. Briefly, Wistar rats (180–220 g) were anaes-
thetized by intra-peritoneal injection of sodium pentobar-
bitone at a dose of 21 mg·kg-1. After shaving the back, 1%
(w/v) Evan's blue dye in normal saline was injected intra-
venously into the tail vein, and then various doses of TM-
N49, bradykinin, histamine and PAF all at 5 μg, BSA at 5
μg and 50 μg or normal saline were intradermally
injected, randomized sites placed 2–3 cm apart, 50 μl per
injection point. Animals were kept warm, and at 20 min
following the final injection, were killed by inhalation of
carbon dioxide and the skin removed. Two perpendicular
diameters were recorded for the blue area on the inside of
the skin, and multiplied to give a measure of the relative
size of the area of cutaneous edema.
For compound 48/80 pretreatment experiments, groups
of rats (including 6 h, day 1, day 2, day 3, day 4 groups
and their corresponding control groups) were treated with
compound 48/80 to deplete mast cells, as described by Di
Rosa et al. [38]. Briefly, compound 48/80 (0.1% solution
in 0.9% sterile saline) was injected intravenously at a dose
of 0.6 mg·kg-1, twice a day for 3 days, and doubled dose
in day 4. At 5 h following the final injection, the test sub-
stances in the skin oedema experiments were adminis-
tered as described above. The control groups received a
normal saline injection. Both skins and peritoneal lavages
of the testing rats were collected and analyzed.
To investigate potential mechanisms involved in TM-N49
induced microvascular leakage, several anti-inflammatory
compounds including cyproheptadine (5 μg), a 5-HT2/5-
HT1Cserotonin receptor antagonist and H1  histamine
receptor antagonist; terfenadine (5 μg), a selective H1 his-
tamine receptor antagonist; ginkgolide B (5 μg), a PAF
receptor antagonist [39] and quinacrine (5 μg), an inhib-
itor of PLA2 [40] were co-injected into the skin of rats with
TM-N49 PLA2 (5 μg), bradykinin (5 μg), histamine (5 μg),
or normal saline respectively for 20 min.
Mast cell challenge and analysis of histamine release
Macroscopically normal lung and colon tissues were col-
lected at bronchial or colon resection from patients with
lung or colon cancer, respectively, and tonsil tissue was
obtained at tonsillectomy. The procedure for mast cell dis-BMC Immunology 2009, 10:21 http://www.biomedcentral.com/1471-2172/10/21
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persion was similar to that described previously [23,28].
Briefly, tissue was chopped finely with scissors into frag-
ments of 0.5–2.0 mm3, and incubated with 1.5 mg/ml
collagenase and 0.75 mg/ml hyaluronidase in MEM con-
taining 2% FCS (1 g lung/10 ml buffer) for 70 min at
37°C. Dispersed cells were separated from undigested tis-
sue by filtration through nylon gauze (pore size 100 μm
diameter), and were maintained in MEM (containing
10% FCS, 200 U/ml penicillin, 200 μg/ml streptomycin)
on a roller overnight at room temperature. Mast cell num-
bers were determined by light microscopy after staining
with alcine blue staining solution, and represented 2.5 to
5.3%, 4.2 to 5.7%, and 1.2 to 3.1% of nucleated cells in
lung, colon or tonsil suspensions, respectively.
Prior to challenge with stimulus the cells were washed
with HBSS (pH 7.4) without added calcium or magne-
sium (500 g, 10 min, 25°C), and then resuspended in
HBSS with 1.8 mM CaCl2 and 0.5 mM MgCl2. Aliquots of
100 μl containing 4–6 × 103 mast cells were added to a 50
μl aliquot of purified TM-N49, heparin, or control secret-
agogue in complete HBSS and incubated for 15 min at
37°C. The reaction was terminated by the addition of 150
μl ice cold HBSS and the tubes centrifuged immediately
(500 g, 10 min, 4°C). All experiments were performed in
duplicate. For the measurement of total histamine con-
centration the suspension in some tubes was boiled for 6
min. Supernatants were stored at -20°C until histamine
concentrations were determined. Where added, TM-N49
at 30 μg/ml was preincubated with heparin on ice for 10
min before being added to cells.
For the experiments with pertussis toxin, cells were incu-
bated with 0.1 or 1.0 μg/ml pertussis toxin for 4 h at 37°C,
and then washed with HBSS before adding stimulus. Sim-
ilarly, for the experiments with metabolic inhibitors, cells
were incubated with 2-deoxy-D-glucose (10 mM) and
antimycin A (1 μM) for 40 min at 37°C before challenged
with stimulus.
A glass fibre-based, fluorometric assay was employed to
determine histamine levels in supernatants, as previously
described [23,28]. Histamine bound to a glass-fibre
matrix (RefLab, Copenhagen, Denmark) was detected by
addition of o-phthaldialdehyde (OPT) and the color
change measured using a spectrophotofluorometer (Per-
kin-Elmer LS 2, Denmark). Histamine release was
expressed as a percentage of total cellular histamine levels,
and corrected for the spontaneous release measured in
tubes in which cells had been incubated with the HBSS
diluent alone. For the time course study, data were pre-
sented as percentage of maximum histamine release,
which equals (actual net histamine release/maximum net
histamine release induced by the testing compound) ×
100%.
Induction of mast cell accumulation
Various doses of TM-N49, BSA or normal saline were
injected in 0.5 ml volumes into the peritoneum of male
BALB/c mice, whose abdominal skin was swabbed with
70% ethanol, a group of 6 mice for each dose. This model
was adapted from that described by Thomas et al. [41],
which complied with the European Community guide-
lines for use of experimental animals. At 10 min, 2 h, 6 h
or 16 h following injection, animals were sacrificed by
inhalation of carbon dioxide, and their peritoneal lavages
were collected following a standardized procedure with 5
ml normal saline using heparinised tubes. After centrifu-
gation at 500 g for 10 min at 4°C, supernatants were col-
lected and stored at -40°C until use, and cells were
resuspended in 1 ml of MEM. The total cell numbers were
determined by enumerating them with an Improved Neu-
bauer haemocytometer after being stained with 0.1%
trypan blue. For the differential cell counting, cytocentri-
fuge preparations were made, air dried and stained with
modified Wright's stain. Differential cell counts were per-
formed for a minimum of 500 cells. The results were
expressed as absolute numbers of each cell type per mouse
peritoneum.
For the experiments investigating mast cell migration
mechanisms, groups of mice were pretreated intrave-
nously (tail vein injection) with monoclonal antibodies
against the adhesion molecules L-selectin, CD11a, CD18
and ICAM-1 (all at a dose of 1 mg·kg-1) [42-44], respec-
tively for 30 min before intra-peritoneal injection of 5 μg
TM-N49. Control animals received an equivalent dose of
the corresponding normal rat or hamster IgG isotype con-
trol. At 6 h following injection, the mice were sacrificed
and their peritoneal lavages were processed as described
above.
To investigate potential mechanisms involved in TM-N49
induced inflammatory cell accumulation, several anti-
inflammatory compounds including cyproheptadine (2
mg·kg-1) [17], terfenadine (3 mg·kg-1) [45,46],
ginkgolide B (5 mg·kg-1) [39] and quinacrine (10 mg·kg-
1) [40] were co-injected into the peritoneum of mice with
TM-N49 (5 μg per mouse). Control animals received an
injection of drug alone. At 6 h following injection, mice
were sacrificed and their peritoneal lavages were proc-
essed as described above. Certain mice were pretreated
with compound 48/80 for 4 days as described above
before peritoneal injection of 5 μg of TM-N49.
Statistical analysis
Statistical analyses were performed using SPSS software
(version 12.0). For in vitro experiments, because data were
normally distributed, they are shown as the mean ± SEM.
for the number of experiments indicated. Where analysis
of variance indicated significant differences betweenBMC Immunology 2009, 10:21 http://www.biomedcentral.com/1471-2172/10/21
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groups, for the preplanned comparisons of interest, paired
Student's t test was applied. For in vivo experiments, since
the data were not normally distributed, they were pre-
sented as the median and range, for the numbers of ani-
mals indicated. Where Kruskal-Wallis analysis indicated
significant differences between groups, for the preplanned
comparisons of interest the Mann-Whitney U-test was
employed. For all analyses, P < 0.05 was taken as signifi-
cant.
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